18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Background:
Prostate cancer is the second leading cause of cancer deaths in American men. Few options
exist to create images of this type of cancer. Researchers think an experimental radiotracer
called 18F-DCFPyL could find sites of cancer in the body.
Objective:
To see if 18F-DCFPyL can identify sites of prostate cancer in people with the disease.
Eligibility:
People ages 18 and older who have metastatic prostate cancer
Design:
Participants will be screened with:
- Blood tests
- Physical exam
- Medical history
Participants will be assigned to 1 of 2 groups based on their PSA.
Participants will have 18F-DCFPyL injected into a vein. About 2 hours later they will have a
whole-body Positron Emission
Tomography/Computed Tomography (PET/CT). For the scan, they will lie on their back on the
scanner table while it takes pictures of the body. This lasts about 50 minutes.
On another day, participants will have 18F -NaF injected into a vein. About 1 hour later,
they will have a whole-body PET/CT.
Participants will be contacted 1 3 days later for follow-up. They may undergo PET/Magnetic
Resonance Imaging (MRI) either after having a 18F-DCFPyL PET/CT, or in place of PET/CT
imaging. A tube may be placed in the rectum. More coils may be wrapped around the outside of
the pelvis.
If the 18F-DCFPyL PET/CT is positive participants will be encouraged to undergo a biopsy of
one of the tumors. The biopsy will be taken through a needle put through the skin into the
tumor.
Participants will be followed for 1 year. During this time researchers will collect
information about their prostate cancer, such as PSA levels and biopsy results.
About 4-6 months after scanning is completed, participants may have a tumor biopsy. The
biopsy will be taken through a needle put through the skin into the tumor.
...